A new pharmacodynamic approach to study antibiotic combinations against enterococci in vivo: Application to ampicillin plus ceftriaxone
ABSTRACT: The combination of ampicillin (AMP) and ceftriaxone (CRO) is considered synergistic against Enterococcus faecalis based on in vitro tests and the rabbit endocarditis model, however, in vitro assays are limited by the use of fixed antibiotic concentrations and the rabbit model by poor bacte...
- Autores:
-
Jiménez Toro, Ivone Eliana
Rodríguez Jaramillo, Carlos Andrés
Zuluaga Salazar, Andrés Felipe
Vesga Meneses, Omar
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/43307
- Acceso en línea:
- https://hdl.handle.net/10495/43307
- Palabra clave:
- Ampicilina
Ampicillin
Ceftriaxona
Ceftriaxone
Quimioterapia
Drug Therapy
Endocarditis
Enterococcus faecalis
Infecciones por Bacterias Grampositivas
Gram-Positive Bacterial Infections
Modelos Animales de Enfermedad
Disease Models, Animal
Quimioterapia Combinada
Drug Therapy, Combination
Endocarditis Bacteriana
Endocarditis, Bacterial
https://id.nlm.nih.gov/mesh/D000667
https://id.nlm.nih.gov/mesh/D002443
https://id.nlm.nih.gov/mesh/D004358
https://id.nlm.nih.gov/mesh/D004696
https://id.nlm.nih.gov/mesh/D013293
https://id.nlm.nih.gov/mesh/D016908
https://id.nlm.nih.gov/mesh/D004195
https://id.nlm.nih.gov/mesh/D004359
https://id.nlm.nih.gov/mesh/D004697
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by/4.0/
| Summary: | ABSTRACT: The combination of ampicillin (AMP) and ceftriaxone (CRO) is considered synergistic against Enterococcus faecalis based on in vitro tests and the rabbit endocarditis model, however, in vitro assays are limited by the use of fixed antibiotic concentrations and the rabbit model by poor bacterial growth, high variability, and the use of point dose-effect estimations, that may lead to inaccurate assessment of antibiotic combinations and hinder optimal translation. Here, we tested AMP+CRO against two strains of E. faecalis and one of E. faecium in an optimized mouse thigh infection model that yields high bacterial growth and allows to define the complete dose-response relationship. By fitting Hill’s sigmoid model and estimating the parameters maximal effect (Emax) and effective dose 50 (ED50), the following interactions were defined: synergism (Emax increase ≥2 log10 CFU/g), antagonism (Emax reduction ≥1 log10 CFU/g) and potentiation (ED50 reduction ≥50% without changes in Emax). AMP monotherapy was effective against the three strains, yielding valid dose-response curves in terms of dose and the index fT>MIC. CRO monotherapy showed no effect. The combination AMP+CRO against E. faecalis led to potentiation (59–81% ED50 reduction) and not synergism (no changes in Emax). Against E. faecium, the combination was indifferent. The optimized mouse infection model allowed to obtain the complete dose-response curve of AMP+CRO and to define its interaction based on pharmacodynamic parameter changes. Integrating these results with the pharmacokinetics will allow to derive the PK/PD index bound to the activity of the combination, essential for proper translation to the clinic. |
|---|
